Market revenue in 2023 | USD 13.7 million |
Market revenue in 2030 | USD 21.6 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.77% in 2023. Horizon Databook has segmented the France cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
In France, there is a growing demand for biologics, such as gene therapies, cell-based therapies, and monoclonal antibodies. Moreover, the French Society for Cell and Gene Therapy is a nonprofit organization that represents the demands of scientists working on the development of innovative cell and gene therapies.
The primary objective of society is to promote the treatment of diseases of all kinds, whether inherited or acquired; these include muscular, metabolic, skin, cancer, neurological, cardiovascular, immunological, hematological, and infectious diseases.
These areas include biotherapies, regenerative medicine, technologies based on gene transfer, and cell biology. The presence of such an organization in the country is boosting the market. Furthermore, in France, market players implement various strategic initiatives to expand their reach and offer services. For instance, in February 2023, Apax Partners acquired Porsolt, a recognized Global CRO.
Horizon Databook provides a detailed overview of country-level data and insights on the France cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into France cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account